Business Wire

PA-PPG

8.8.2016 14:12:52 CEST | Business Wire | Press release

Share
PPG Completes COLORFUL COMMUNITIES Project in Soborg, Denmark

PPG (NYSE:PPG) today announced the completion of a COLORFUL COMMUNITIES™ project in Soborg, Denmark, that helped to revitalize and add shelter and seating to the parkour area of the City’s Arena, an outdoor activity space adjacent to the Hoje Gladsaxe housing project. The Colorful Communities program provides PPG employees and products along with financial contributions to bring color and vitality to communities where our company operates around the world. The program increases PPG’s commitment to invest in communities by adding $10 million to support efforts made during a 10-year period.

The project brought together more than 30 volunteers who are employees at PPG’s nearby architectural coatings, automotive refinish, and protective and marine coatings operations in Soborg to spend two days revitalizing the parkour area. PPG provided more than $18,500 for the project, as well as about 150 liters of DYRUP® Façade Extra paint products in 10 colors.

Young residents who use the City's Arena (Byens Arena) – an outdoor area that encourages movement, activity and play, mostly for residents of the adjacent 2,500-unit Hoje Gladsaxe housing project – expressed a desire for development and beautification of the parkour area. There was a need to make the area more welcoming in the hope of inviting more use. Large concrete features were installed to provide shelter and accommodation for visitors, and artist Anders Benmouyal facilitated a workshop where PPG employees and Hoje Gladsaxe residents came together and decorated the new concrete features.

“From the beginning, we were sure that revitalizing an area of Hoje Gladsaxe was right for this project – the residents are so close to our site, they are actually our neighbors,” said Peter Soerensen, PPG general manager, architectural coatings, Denmark. “We hope this is the beginning of close cooperation on more community initiatives. Already we are planning an educational day at our PPG site for local school students.”

The Colorful Communities program is PPG’s signature initiative for community engagement efforts, with the aim to protect and beautify the neighborhoods where PPG operates around the world. Together with community partners and PPG employees who volunteer, the program supports projects that transform community assets using donated PPG products. In 2015, PPG completed 11 Colorful Communities projects, and it expects to complete about 30 more this year.

PPG and the PPG Foundation aim to bring color and brightness to PPG communities around the world. We donated more than $7.8 million in 2015 to hundreds of community organizations across 20 countries. By investing in educational opportunities, we help grow today’s skilled workforce and develop tomorrow’s innovators in industries related to coatings and specialty materials. Plus, we empower PPG employees to make an impact for causes that are important to them by supporting their volunteer efforts and charitable giving. Learn more at www.ppgcommunities.com and follow @PPG_Communities on Twitter.

PPG: WE PROTECT AND BEAUTIFY THE WORLD™

At PPG (NYSE:PPG), we work every day to develop and deliver the paints, coatings and materials that our customers have trusted for more than 130 years. Through dedication and creativity, we solve our customers’ biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 70 countries and reported net sales of $15.3 billion in 2015. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit www.ppg.com .

We protect and beautify the world and Colorful Communities are trademarks and the PPG Logo is a registered trademark of PPG Industries Ohio, Inc.

Dyrup is a registered trademark of Dyrup A/S.

Contact:

PPG Media:
Mark Silvey, +1 412-434-3046
Corporate Communications
silvey@ppg.com
www.ppgcommunities.com

Social Media:

https://www.facebook.com/ppgindustries

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye